Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 16, 2021

SELL
$1.39 - $3.47 $28,014 - $69,934
-20,154 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$3.24 - $6.92 $255,441 - $545,572
-78,840 Reduced 79.64%
20,154 $71,000
Q1 2021

May 17, 2021

BUY
$6.34 - $12.68 $627,621 - $1.26 Million
98,994 New
98,994 $678,000

Others Institutions Holding VYNE

About VYNE Therapeutics Inc.


  • Ticker VYNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,005,600
  • Market Cap $170M
  • Description
  • VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, whi...
More about VYNE
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.